



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 14/11/2019

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Sub: - :-Outcome of Board Meeting and Submission of Standalone UnAudited Financial Results for the Quarter as well as Half Year ended 30 th September, 2019 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scripe Code: 524396; Sripe Id: BIOFILCHEM; ISIN: INE829A01014

This is in continuation of our letter dated 6th November 2019, regarding information for Board Meeting for consideration and approval of Standalone Un-Audited Financial Results for the quarter as well as half year ended on 30th September, 2019.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Standalone Un-Audited Financial Results for the quarter as well as half year ended 30th September, 2019, duly approved by the Board of Directors of the Company at its meeting held on today i.e. Thursday 14th November, 2019 together with Limited Review Report thereon in respect of unaudited financial results.

Further, pursuant to Regulation 33(3)(f) and (g) of the Listing Regulations, we have also. enclosed Statements of Assets and Liabilities and the Statement of Cash flow in the prescribed format for the quarter as well as half year ended 30 September, 2019.

Further, copy of Un-Audited Financial Statements also Submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the Conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.



[Handwritten signature]

The Meeting of the Board of Directors commenced at 6.00 P.M. and concluded at 7:30 P.M.
Kindly take above said financial results for your reference and record. Thanking you. Yours
Faithfully,

Thanking You ,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah

**Ramesh Shah
Managing Director
DIN:00028819**



Particulars	Quarter Ended			Half Year Ended		Audited for the year ended March 31 2019
	3 months ended (30/09/2019)	Preceding 3 months ended (30/06/2019)	Corresponding 3 months ended in the previous year (30/09/2018)	Year to date figures for current period ended (30/09/2019)	Year to date figures for the previous year ended (30/09/2018)	
	Un- audited	Un- audited	Un- audited	Un- audited	Un-audited	
I Revenue from Operation	1162.88	159.41	213.60	1322.29	636.01	2312.85
II Other Income	3.36	1.11	2.00	4.47	3.66	10.12
III Total Revenue (I + II)	1166.24	160.52	215.61	1326.77	639.67	2322.98
IV Expenses						
(a) Cost of materials consumed	97.60	86.67	20.52	184.27	32.81	77.27
(b) Purchases of stock-in-trade	2119.94	25.03	864.49	2144.97	1277.63	1904.95
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,205.14)	(13.95)	(738.74)	(1,219.09)	(798.14)	17.04
(d) Employee benefits expense	21.46	18.97	20.19	40.43	41.39	89.22
(e) Finance Cost	3.27	3.59	3.92	6.86	7.79	16.03
(f) Depreciation and Amortisation Expense	9.45	9.13	7.11	18.58	14.60	36.51
(g) Other expenses	40.53	27.19	27.64	67.72	46.72	122.12
Total expenses (IV)	1087.11	156.64	205.13	1243.75	622.79	2263.15
V Profit (Loss) before exceptional items and tax (III-IV)	79.13	3.89	10.48	83.02	16.88	59.83
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII Profit (Loss) before tax (V - VI)	79.13	3.89	10.48	83.02	16.88	59.83
VIII Tax expense:						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	11.60
(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	0.00
IX Profit (Loss) for the period from continuing operation VII-VIII)	79.13	3.89	10.48	83.02	16.88	48.23
X Profit (Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII Profit (Loss) for the period (IX+XII)	79.13	3.89	10.48	83.02	16.88	48.23
XIV Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
A) (i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss						
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to Profit or Loss						
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	79.13	3.89	10.48	83.02	16.88	48.23
XVI Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII Reserves (Excluding Revaluation Reserve)						(638.63)
XVIII Earnings per equity shares (for continuing operation):						
(1) Basic (Rs)	0.49	0.02	0.06	0.51	0.10	0.30
(2) Diluted (Rs)	0.49	0.02	0.06	0.51	0.10	0.30

1. The above unaudited results for the Quarter and half year ended September 30, 2019 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 14.11.2019. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.



(Handwritten signature)

2. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- I. Pharma Product
- II. Chemicals Division
- III. Plastic Division

3. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

4. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

5. The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

6. The Company has adopted ND AS 116 "Leases" effective from 01.04.2019 and applied standard to its Leases.

7. Pursuant to Regulation 33(3)(f) and (g) of the Listing Regulations Statements of Assets and Liabilities and the Statement of Cash flow in the prescribed format for the half year ended 30th September, 2019 is enclosed herewith.

Date : 14-11-2019

Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)



Biofil Chemicals and Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results an Capital Employed for year half year ended 30th Sept 2019

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		
		Sep 30 ,	June 30 ,	Sep 30 ,	Sep 30 ,	Sep 30 ,	31 March
		2019	2019	2018	2019	2018	2019
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
		30.09.2019	30-06-2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
1	Segment Revenue						
	Pharma Unit	998.46	55.59	147.85	1,054.05	529.28	1,053.13
	Chemicals Division	164.42	103.82	65.75	268.24	106.73	180.02
	Plastic Division	0.00	0.00	0.00	0.00	2.84	2.84
	Other	2.32	1.11	2.00	3.43	3.66	10.07
	Gross Turnover	1,165.20	160.52	215.61	1,325.73	642.52	1,246.07
2	Segment Results						
	Pharma Unit	67.82	8.06	12.90	75.88	17.52	56.31
	Chemicals Division	14.57	2.96	5.20	17.53	11.89	26.91
	Plastic Division	(1.06)	(3.56)	(3.88)	(4.63)	(4.95)	(4.01)
	Other		0.00		0.00	0.00	(8.41)
	Total Segment Profit Before Tax	81.33	7.45	14.23	88.79	24.46	70.79
	Interest Income	1.04	0.00		1.04	0.00	3.03
	Interest Expenses	3.25	3.56	3.75	6.81	7.58	15.00
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	79.13	3.89	10.48	83.02	16.88	58.82
	Provision for current tax	0.00	0.00	0.00	0.00	0.00	11.30
	Item Related Earlier Year	0.00	0.00	0.00	0.00	0.00	0.45
	Profit After Tax	79.13	3.89	10.48	83.02	16.88	47.07
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	3,424.07	1,340.63	1,601.67	3,424.07	1,601.67	1,485.86
	Chemicals Division	1,073.39	1,014.01	959.84	1,073.39	959.84	866.71
	Plastic Division	51.11	50.05	120.70	51.11	120.70	62.89
	Other						
	Total (A)	4,548.57	2,404.69	2,682.21	4,548.57	2,682.21	2,415.46
	Segment Liabilities (B)						
	Pharma Division	2,762.38	735.37	1,079.07	2,762.38	1,079.07	898.26
	Chemicals Division	175.91	180.20	64.29	175.91	64.29	41.52
	Plastic Division	143.71	150.79	166.03	143.71	166.03	158.96
	Other				0.00	0.00	
	Total (B)	3,082.00	1,066.35	1,309.39	3,082.00	1,309.39	1,098.74
	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	661.69	605.27	522.60	661.69	522.60	587.60
	Chemicals Division	897.48	833.81	895.56	897.48	895.56	825.19
	Plastic Division	(92.60)	(100.74)	(45.33)	(92.60)	(45.33)	(96.07)
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,466.57	1,338.34	1,372.83	1,466.57	1,372.83	1,316.73

DATE : 14-11-2019
PLACE : INDORE



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Ramesh Shah

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819

Biofil Chemicals and Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Statement of Assets & Liabilities for half year ended as on 30th Septemeber, 2019

(Amount in Lakhs)

Particulars	Unaudited As at 30/09/2019	Audited As at 31/03/2019
A ASSETS		
1 Non-current assets:		
(a) Property, Plant & Equipment	1022.17	1029.42
(b) Capital work in Progress		
(c) Other Intangible Assets		
(d) Financial Assets:		
i. Investments		
ii. Other Financial Assets		
(e) Other Non- Current Assets		
Sub-total - Non-current assets	1022.17	1029.42
2 Current assets		
(a) Inventories	1359.72	119.09
(b) Financial Assets:		
(i) Trade receivables	1871.86	1202.50
(ii) Cash and cash equivalents	6.75	5.64
(iii) Bank balances other than (ii) above	14.10	7.98
(iv) Loans	20.00	24.99
(v) Other Financial Assets		
(c) Current Tax Assest (Net)		
(d) other Currents Assets	238.94	31.68
(e) Assets classified as held for sale		
Sub-total - Current assets		
TOTAL - ASSETS	4533.55	2421.30
B EQUITY AND LIABILITIES		
1 Equity		
(i) Equity Share Capital	1627.38	1627.38
(ii) Other Entity	(179.39)	(262.41)
Sub-total- Equity	1447.99	1364.97
2 Non-current Liabilities :		
a Financial Liabilities		
(i) Borrowings		
(ii) other Financial Liabilities		
b Provisions		
c Deferred tax liabilities (net)		
d Other Non-current Liabilities		
Sub-total - Non-current liabilities	1447.99	1364.97
3 Current liabilities		
a Financial Liabilities		
(i) Borrowings	143.71	163.73
(ii) Trade Payables	2927.92	858.34
(A) total outstanding dues of micro enterprises and small enterprises; and		
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		
(iii) other Financial Liabilities		
b Other Current Liabilities		
c Provisions	13.92	34.26
d Current Tax Liabilities (Net)		
Sub-total - Current liabilities	3085.56	1056.33
TOTAL - EQUITY AND LIABILITIES	4533.55	2421.30

Date : 14/11/2019
Place : INDORE



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Ramesh Shah

RAMESH SHAH
MANAGING DIRECTOR
(DIN NO. 00028819)

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709
Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Statement of cash flows for the year half year ended 30th Sept 2019

(Amount in Lakhs)

Particulars	HALF YEAR ENDED ON 30.09.19	HALF YEAR ENDED ON 30.09.18	For the year ended March 31, 2019
Cash flow from operating activities			
Profit before tax	83.02	16.88	59.83
Adjustments to reconcile profit before tax to net cash used in operating activities			
Depreciation of property, plant and equipment	18.58	14.60	36.51
Finance cost	6.86	7.79	16.03
Net (gain)/ loss on derivative contracts on account of Ind AS adjustments			
Provision for doubtful advances/debts	108.46	39.27	112.38
Working capital adjustments			
Increase/ (Decrease) in Inventory	(1240.63)	(638.26)	(16.61)
(Increase)/ Decrease in Trade Receivable	(669.36)	570.76	95.58
(Increase)/ Decrease in other current assets	(202.27)	(138.19)	(3.90)
Increase/ (Decrease) in trade payables	2069.58	212.88	(55.83)
Increase/ (Decrease) in other financial liabilities			5.34
Increase/ (Decrease) in other liabilities	(8.74)	(15.96)	0.00
Cash generated from operations	57.04	30.49	136.96
Current tax assets	(11.60)	(11.51)	(11.39)
Net cash flows from operating activities	45.44	18.98	125.57
Cash flow from investing activities			
Payment for purchase and construction of property, plant and equipment	(11.33)	(37.70)	(141.25)
Proceeds from sale of property, plant and equipment	0.00	0.00	0.00
(Increase)/ Decrease in other bank balances			0.00
Interest received			0.00
Net cash flows from investing activities	(11.33)	(37.70)	(141.25)
Cash flow from financing activities			
Increase/(decrease) in Borrowings	(20.02)	6.94	7.88
Deemed Investment by Holding Company			0.00
Finance cost	(6.86)	(7.79)	(16.03)
Net cash flows from financing activities	(26.88)	(0.85)	(8.16)
Net increase / (decrease) in cash and cash equivalents	7.23	(19.56)	(23.83)
Cash and cash equivalents at the beginning of the year	13.62	37.45	37.45
Cash and cash equivalents at the end of the year	20.85	17.89	13.62
Increase /(Decrease) in cash and cash equivalents	7.23	(19.56)	(23.83)





Limited Review Report

(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements))

To Board of Director

Biofil Chemicals and Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended **30th September 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Indore
Date: 14.11.2019

For Maheshwari & Gupta
Chartered Accountant
FRN: 006179C



CA Sumil Maheshwari
Partner
M No.403346